<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>PBC Primary Biliary Cholangitis • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="PBC Primary Biliary Cholangitis • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/PBC primary biliary cholangitis/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/PBC primary biliary cholangitis/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="primary-biliary-cholangitis" tabindex="-1">primary biliary cholangitis</h1>
<ul>
<li>related: <a href="/wiki/notes/GI/">GI</a>, <a href="/wiki/notes/PSC%20primary%20sclerosing%20cholangitis/">PSC primary sclerosing cholangitis</a></li>
<li>tags: #GI</li>
</ul>
<hr>
<!-- primary biliary cholangitis demographics, sx, dx b:538641649135-->
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220809210448.png" alt=""></p>
<p>Primary biliary cholangitis (PBC), previously termed primary biliary cirrhosis, is an <mark>autoimmune disease affecting the small and medium bile ducts</mark> with a <mark>female to male predominance</mark> of 9 to 1. It is more common in individuals of <mark>European descent</mark>. PBC can present with <mark>fatigue and pruritus</mark>, but many patients are <mark>asymptomatic</mark>, with the diagnosis suggested by <mark>elevated ALP levels</mark>. Diagnosis does not require liver biopsy when the ALP is at least 1.5 times the upper limit of normal and <mark>antimitochondrial antibody (AMA) testing</mark> is positive, or when other PBC-specific autoantibodies, including sp100 or gp210, are present if antimitochondrial antibody testing is negative. In patients with negative antibody test results and strong suspicion for PBC, a <mark>liver biopsy is necessary</mark>. <mark>Transient or MRI elastography</mark> can be used for fibrosis staging.</p>
<!-- primary biliary cholangitis rx b:1597452335922-->
<p>The initial treatment is <mark>ursodeoxycholic acid</mark>. Response to treatment is defined by <mark>improvement of ALP level</mark> to less than 1.67 times the upper limit of normal. Patients whose disease does not respond to ursodeoxycholic acid should receive <mark>obeticholic acid</mark>. Dose reductions are required for obeticholic acid use in patients with <mark>decompensated cirrhosis</mark> to avoid worsening liver failure. Ursodeoxycholic acid treatment results in histologic improvement, better survival rates, and diminished need for liver transplantation. Patients who present with normal bilirubin and albumin levels and respond to treatment have a life expectancy similar to that of individuals without PBC.</p>
<p>PBC is associated with other autoimmune conditions, particularly <mark>autoimmune thyroid disease</mark>. Therefore, in patients with PBC, <mark>thyroid-stimulating hormone level</mark> should be checked on a <mark>yearly basis</mark>. In patients with a PBC score of 4.1 or greater, <mark>upper endoscopy</mark> is indicated to assess for <mark>esophageal varices</mark>. <mark>First-degree relatives</mark> of patients with PBC, especially women, should be screened by <mark>checking their ALP level periodically</mark>. Patients with advanced disease should be managed like other patients with cirrhosis and portal hypertension (see <a href="https://mksap18.acponline.org/app/topics/gi/mk18_a_gi_s6/mk18_a_gi_s6_10_1">Complications of Advanced Liver Disease</a>). In addition, the American Association for the Study of Liver Diseases recommends screening for hepatocellular carcinoma with <mark>ultrasonography at 6-month intervals</mark> for men and patients with cirrhosis. Patients should ensure dietary intake of 1000 to 1500 mg of <mark>calcium and 1000 IU of vitamin D daily</mark>, with supplements if needed. Patients are at increased risk for <mark>osteoporosis</mark>; appropriate screening and treatment with bisphosphonate therapy should be considered. Patients with <mark>elevated lipid levels</mark> may be at risk for cardiovascular disease and can be considered for <mark>lipid-lowering therapy</mark>. Fat-soluble vitamin deficiencies should be treated with parenteral or water-soluble supplements. Liver transplant outcomes for patients with PBC are excellent, with a 1-year survival rate greater than 90% and a recurrence rate of approximately 20% at 5 years after liver transplantation.</p>
<p>Up to 50% of patients develop metabolic bone disease, which may manifest as <strong>osteoporosis</strong> and/or <strong>osteomalacia</strong>.  The cause of osteoporosis in PBC is unknown but is thought to be due to cholestasis leading to an accumulation of substances that inhibit bony turnover.  Additionally, the disease predominately affects middle aged female patients who are already at risk for osteoporosis.  Patients may have malabsorption of fat-soluble vitamins, but those with PBC-related osteoporosis usually have normal vitamin D levels.  Nevertheless, patients with PBC should receive routine supplementation with calcium and vitamin D in addition to regular bone density screening.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/PSC primary sclerosing cholangitis/" class="peer">PSC Primary Sclerosing Cholangitis</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="psc" tabindex="-1">PSC</h1>
<ul>
<li>related: <a href="/wiki/notes/GI/">GI</a>, <a href="/wiki/notes/PBC%20primary%20biliary%20cholangitis/">PBC primary biliary cholangitis</a></li>
<li>tags: #GI</li>
</ul>
<hr>
<h3 id="primary-sclerosing-cholangitis" tabindex="-1">Primary Sclerosing Cholangitis</h3>
<!-- PSC pathogenesis b:206694913956-->
<p>Primary sclerosing cholangitis (PSC) is an <mark>autoimmune fibroinflammatory disease of the large bile ducts</mark>, but it can also affect the small bile ducts (small-duct PSC). It is more common in <mark>men than in women</mark>, which is unique among the autoimmune liver diseases. PSC is associated with inflammatory bowel disease (IBD)</p>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Disorders of the Liver/" class="peer">Disorders of the Liver</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="disorders-of-the-liver" tabindex="-1">Disorders of the Liver</h1>
<ul>
<li>related: <a href="/wiki/notes/GI/">GI</a></li>
<li>tags: #GI</li>
</ul>
<hr>
<h2 id="approach-to-the-patient-with-abnormal-liver-chemistry-studies" tabindex="-1">Approach to the Patient with Abnormal Liver Chemistry Studies</h2>
<ul>
<li><a href="/wiki/notes/HCC%20hepatocellular%20carcinoma/">HCC hepatocellular carcinoma</a></li>
</ul>
<p>Basic metabolic panels commonly include liver chemistry tests. Liver chemistry tests are often abnormal (10% to 20% of the time); therefore, it is important to take a systematic approach to their evaluation. The patterns of the elevations of liver tests can be used to group causes into categories; however, these pa</p>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
